- Home
- CISO vs MYNZ Comparison
CISO vs MYNZ Comparison
Compare CISO & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISO
- MYNZ
- Stock Information
- Founded
- CISO 2015
- MYNZ 2021
- Country
- CISO United States
- MYNZ Germany
- Employees
- CISO N/A
- MYNZ N/A
- Industry
- CISO Computer Software: Prepackaged Software
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- CISO Technology
- MYNZ Health Care
- Exchange
- CISO Nasdaq
- MYNZ Nasdaq
- Market Cap
- CISO 31.4M
- MYNZ 7.9M
- IPO Year
- CISO N/A
- MYNZ 2021
- Fundamental
- Price
- CISO $1.29
- MYNZ $1.60
- Analyst Decision
- CISO
- MYNZ Buy
- Analyst Count
- CISO 0
- MYNZ 2
- Target Price
- CISO N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- CISO 685.4K
- MYNZ 67.8K
- Earning Date
- CISO 11-17-2025
- MYNZ 10-21-2025
- Dividend Yield
- CISO N/A
- MYNZ N/A
- EPS Growth
- CISO N/A
- MYNZ N/A
- EPS
- CISO N/A
- MYNZ N/A
- Revenue
- CISO $28,792,765.00
- MYNZ $893,991.00
- Revenue This Year
- CISO N/A
- MYNZ $26.06
- Revenue Next Year
- CISO N/A
- MYNZ $4.97
- P/E Ratio
- CISO N/A
- MYNZ N/A
- Revenue Growth
- CISO N/A
- MYNZ N/A
- 52 Week Low
- CISO $0.30
- MYNZ $1.30
- 52 Week High
- CISO $3.84
- MYNZ $16.04
- Technical
- Relative Strength Index (RSI)
- CISO 68.68
- MYNZ 44.52
- Support Level
- CISO $1.21
- MYNZ $1.56
- Resistance Level
- CISO $1.47
- MYNZ $1.79
- Average True Range (ATR)
- CISO 0.11
- MYNZ 0.10
- MACD
- CISO 0.04
- MYNZ -0.01
- Stochastic Oscillator
- CISO 70.30
- MYNZ 18.80
About CISO CISO Global Inc.
CISO Global Inc provides cybersecurity services. The services are used to protect client's data, financial information, intellectual property, and business reputation. The services include penetration testing, security remediation, compliance auditing, vulnerability assessment, and others. Geographically, the company operates in U.S., Chile and All other countries. The maximum revenue is generated from U.S.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.